<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01958073</url>
  </required_header>
  <id_info>
    <org_study_id>130403</org_study_id>
    <nct_id>NCT01958073</nct_id>
  </id_info>
  <brief_title>Vaginal Estrogen for the Prevention of Recurrent Urinary Tract Infection in Postmenopausal Women</brief_title>
  <acronym>VESPR</acronym>
  <official_title>Vaginal Estrogen for the Prevention of Recurrent Urinary Tract Infection in Postmenopausal Women: A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Urogynecologic Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators would like to know if the use of vaginally applied estrogen can prevent the&#xD;
      problem of repeated urinary tract infections (UTI) in women who have gone through menopause.&#xD;
      The investigators will use two forms of vaginal estrogen that are available by prescription&#xD;
      (a ring and a cream) and compare their efficacy to that of a placebo (without any active&#xD;
      ingredient). The investigators are going to look at if the vaginal estrogen can prevent UTIs&#xD;
      altogether and also the number of UTIs each group experiences over a 6 month period. After 6&#xD;
      months, all subjects will receive vaginal estrogen and the women on the non-active treatment&#xD;
      will be able to choose whether they would like to use either the estrogen ring or cream. The&#xD;
      investigators will then be able to compare the number of UTIs on and off active vaginal&#xD;
      estrogen treatment within those subjects who started on the placebo. The investigators are&#xD;
      also going to look at quality of life before and during treatment using questionnaires and&#xD;
      whether subjects stop using the treatments or do not use them as directed (compliance).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was an investigator-initiated, multicenter, single-blind, randomized placebo-controlled&#xD;
      trial of vaginal estrogen (delivered by estradiol ring or conjugated estrogen cream) compared&#xD;
      to placebo cream. This study was conducted by the Divisions of Female Pelvic Medicine and&#xD;
      Reconstructive Surgery at three academic institutions.&#xD;
&#xD;
      Potential participants were recruited from women receiving care for rUTIs in the clinics of&#xD;
      each institution. Women were postmenopausal as defined by amenorrhea for &gt;12 months, history&#xD;
      of bilateral salpingoophrectomy, or in patients with prior hysterectomy defined as menopausal&#xD;
      symptoms for &gt;1 year or age &gt;55. Participants had documented rUTI (three or more in one year&#xD;
      or two in six months) by positive urine culture. Participants were excluded if they had&#xD;
      undergone urologic surgery within three months of screening or planned surgery within one&#xD;
      year of screening, had the diagnosis of painful bladder syndrome, history of UTI requiring&#xD;
      the use of intravenous antibiotics or one oral antibiotic available for treatment based on&#xD;
      allergies and resistance profiles, known etiology of infections (e.g. urologic stones,&#xD;
      fistulas, fecal incontinence, catheterization or poorly controlled diabetes), urothelial&#xD;
      cancer, or actively treated estrogen sensitive tumor. Participant enrollment was deferred in&#xD;
      the setting of undiagnosed hematuria or vaginal bleeding, but enrollment could occur after&#xD;
      negative workup for malignancy. Participants deferred enrollment if they used vaginal&#xD;
      androgens, estrogens or progestins within six months or if they used medications or&#xD;
      supplements known to prevent UTI (e.g. cranberry products, D mannose, prophylactic&#xD;
      antibiotics, methenamine hippurate) within three months of enrollment, but could enroll after&#xD;
      washout. Those with a remote history of estrogen-sensitive tumor required approval by her&#xD;
      oncologist or primary care physician.&#xD;
&#xD;
      Participants were initially randomized to receive either vaginal estrogen (via estradiol ring&#xD;
      or conjugated estrogen cream) or placebo cream in a 1:1:1 fashion and were told that there&#xD;
      were placebo and vaginal estrogen arms, but were unaware that there was not a placebo ring.&#xD;
      Participants were randomized to either conjugated estrogen cream at a strength of 0.625 mg/g&#xD;
      dosed at 0.5g (0.312 mg) twice a week, estradiol ring containing 2mg of estradiol placed&#xD;
      vaginally every three months by study personnel, or placebo cream which was an&#xD;
      over-the-counter lubricant containing mineral oil, petrolatum, ceresin and paraffin dosed at&#xD;
      0.5g twice a week. If participants in any arm developed three UTI in the six-month treatment&#xD;
      period, they were unblinded. If on placebo, they were provided active study drug or if they&#xD;
      were in the vaginal estrogen arm, they were treated according to the provider's clinical&#xD;
      practice and their outcomes recorded for the remainder of the study. The primary outcome of&#xD;
      occurrence of UTI was assessed at six months or the end of study blinding, whichever occurred&#xD;
      first. In order to improve recruitment and assess long-term compliance, satisfaction and&#xD;
      efficacy, we offered open label use of estradiol ring or conjugated estrogen cream after&#xD;
      unblinding until month 12 of the study.&#xD;
&#xD;
      Clean-catch urine cultures were collected when participants were symptomatic: fever (&gt;38&#xD;
      degrees C), urgency, frequency, dysuria or suprapubic tenderness. Women were asked to have&#xD;
      all urine labs done at the parent site as per standard clinical practice. The primary outcome&#xD;
      of the study was the presence of a UTI in the randomized six months. We also assessed rates&#xD;
      of UTI over the course of the 12-month study in all participants as-treated. Quality of life&#xD;
      (QOL) questionnaires were administered at baseline, six months or unblinding, and 12 months.&#xD;
      Questionnaires included the Pelvic Floor Distress Inventory (PFDI-20), Pelvic Floor Impact&#xD;
      Questionnaire (PFIQ-7), Medical, Epidemiologic, and Social Aspects of Aging Questionnaire&#xD;
      (MESA), Female Sexual Function Index (FSFI) and Patient Satisfaction Questionnaire (PSQ),&#xD;
      Global Perception of Improvement (GPI) and Estimated Percent Improvement (EPI) rating scales.&#xD;
      Baseline medical history and concomitant pelvic medicine diagnoses were also collected.&#xD;
      Participants using a cream treatment were asked to keep medication diaries and return tubes&#xD;
      for weighing at months three, six, nine and 12. Adherence was defined as presence of the&#xD;
      estrogen ring or tube weights within 20% of expected at follow up visits. In addition, before&#xD;
      unblinding, the participants were asked whether they believed they were on active treatment,&#xD;
      placebo, or were unsure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of UTI During Randomization</measure>
    <time_frame>6 months of the randomized period</time_frame>
    <description>The primary purpose of this study is to assess the efficacy of vaginal estrogen versus placebo at 6 months on the prevention of urinary tract infections (UTI) in postmenopausal women with history of recurrent UTI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates of UTI in Both Randomization Period and Within Placebo When Changed to Open Label Estrogen</measure>
    <time_frame>Assessed at 6 months for 'a'; assessed over 12 months for 'b'</time_frame>
    <description>To assess overall rates of UTI over 6 months in postmenopausal women with history of recurrent UTI receiving vaginal estrogen (ring or cream).&#xD;
To compare rates of UTI between 6 and 12 months of those subjects initially randomized to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Questionnaire: Female Sexual Function Index</measure>
    <time_frame>6 months of the randomized period</time_frame>
    <description>To assess the impact of treatment of recurrent UTI with vaginal estrogen on quality of life at 6 months in postmenopausal women with history of recurrent UTI. Female Sexual Function Index. Scale range 2-95. Lower score corresponds to worse functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance During Randomization</measure>
    <time_frame>6 months of the randomized period</time_frame>
    <description>To assess compliance with vaginal estrogen (ring or cream) treatment at 6 months in postmenopausal women with history of recurrent UTI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of UTI in Those Compliant With Treatment During Randomization</measure>
    <time_frame>6 months of the randomized period</time_frame>
    <description>To assess efficacy of vaginal estrogen at 6 months in those compliant with treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Questionnaire: MESA I</measure>
    <time_frame>6 months of the randomized period</time_frame>
    <description>To assess the impact of treatment of recurrent UTI with vaginal estrogen on quality of life at 6 months in postmenopausal women with history of recurrent UTI. Medical, Epidemiologic, and Social Aspects of Aging Questionnaire (MESA) urinary incontinence questionnaire: stress urinary incontinence subscale. Subscale range 0-27. A higher score indicated more frequent symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Questionnaire: MESA II</measure>
    <time_frame>6 months of the randomized period</time_frame>
    <description>To assess the impact of treatment of recurrent UTI with vaginal estrogen on quality of life at 6 months in postmenopausal women with history of recurrent UTI. Medical, Epidemiologic, and Social Aspects of Aging Questionnaire (MESA) urinary incontinence questionnaire: urgency urinary incontinence subscale. Subscale range 0-18. High score indicates more frequent symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Questionnaire: Pelvic Floor Disability Index</measure>
    <time_frame>6 months of the randomized period</time_frame>
    <description>To assess the impact of treatment of recurrent UTI with vaginal estrogen on quality of life at 6 months in postmenopausal women with history of recurrent UTI. Pelvic Floor Disability Index. Scale range 0-100. Higher score corresponds to increased bother.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Questionnaire: Pelvic Floor Impact Questionnaire</measure>
    <time_frame>6 months of the randomized period</time_frame>
    <description>To assess the impact of treatment of recurrent UTI with vaginal estrogen on quality of life at 6 months in postmenopausal women with history of recurrent UTI. Pelvic Floor Impact Questionnaire. Scale range 0-300. Higher score corresponds to increasing bother.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Questionnaire: Estimated Percentage of Improvement</measure>
    <time_frame>6 months of the randomized period</time_frame>
    <description>To assess the impact of treatment of recurrent UTI with vaginal estrogen on quality of life at 6 months in postmenopausal women with history of recurrent UTI. Estimated Percentage of Improvement. Scale range 0-100. Higher score corresponds to more improvement.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Recurrent Urinary Tract Infection</condition>
  <arm_group>
    <arm_group_label>Conjugated Estrogen Vaginal Cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conjugated estrogen vaginal cream 0.5g per vagina 2 times weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Estradiol Ring</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Estradiol Ring per vagina every 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Per vagina</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conjugated Estrogen Vaginal Cream</intervention_name>
    <arm_group_label>Conjugated Estrogen Vaginal Cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol Ring</intervention_name>
    <arm_group_label>Estradiol Ring</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Postmenopausal status as defined by amenorrhea for &gt;12 months, OR history of bilateral&#xD;
             salpingoophrectomy, OR if the patient has had a hysterectomy defined by menopausal&#xD;
             symptoms for &gt;1 year OR age &gt;55&#xD;
&#xD;
          2. Documented recurrent UTIs (3 or more in the last year or 2 or more in the last 6&#xD;
             months)- one UTI must be documented by culture, others may be documented by urinalysis&#xD;
&#xD;
          3. Ability to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Use of any investigational drug or device within thirty days of screening&#xD;
&#xD;
          2. Urologic surgery within the past 3 months of screening or plan for surgery within one&#xD;
             year of screening&#xD;
&#xD;
          3. Diagnosis of Interstitial Cystitis/painful bladder syndrome&#xD;
&#xD;
          4. History of urinary tract infections which require the use of IV antibiotics or where&#xD;
             only one oral antibiotic is available for treatment, or where the risk of treatment&#xD;
             with vaginal estrogen only is deemed unacceptable by the principle investigator&#xD;
             secondary to the severity of prior urinary tract infections&#xD;
&#xD;
          5. Known etiology of infection such as, but not limited to: kidney or bladder stones,&#xD;
             enterovaginal/vesical fistula, fecal incontinence, intermittent catheterization,&#xD;
             indwelling catheter, poorly controlled diabetes&#xD;
&#xD;
          6. Urothelial cancer&#xD;
&#xD;
          7. Actively treated estrogen sensitive tumor (breast or endometrial cancer)&#xD;
&#xD;
          8. Undiagnosed vaginal bleeding&#xD;
&#xD;
          9. Inability to use a vaginal ring (secondary to advanced prolapse or shortened vaginal&#xD;
             length)&#xD;
&#xD;
         10. Any medical reason the investigator deems incompatible with treatment with vaginal&#xD;
             estrogen&#xD;
&#xD;
         11. Prolapse requiring pessary use&#xD;
&#xD;
        Deferral Criteria&#xD;
&#xD;
          1. Undiagnosed hematuria - may enroll after malignancy is ruled out&#xD;
&#xD;
          2. Use of a progestin containing intrauterine device or use of any vaginal androgens,&#xD;
             estrogens or progestins within 3 months of enrollment - may enroll after wash out&#xD;
&#xD;
          3. Use of drugs/supplements known to prevent UTIs (ie cranberry products, prophylactic&#xD;
             antibiotics, methenamine hippurate) 1 month prior to enrollment - may enroll after&#xD;
             wash out if still meets inclusion criteria.&#xD;
&#xD;
          4. History of estrogen sensitive tumor (breast or endometrial cancer) - requires approval&#xD;
             by the subject's primary oncologist or primary care physician&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>March 27, 2013</study_first_submitted>
  <study_first_submitted_qc>October 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2013</study_first_posted>
  <results_first_submitted>December 30, 2018</results_first_submitted>
  <results_first_submitted_qc>August 26, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 21, 2020</results_first_posted>
  <last_update_submitted>August 26, 2020</last_update_submitted>
  <last_update_submitted_qc>August 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>NYU Langone Health</investigator_affiliation>
    <investigator_full_name>Kimberly Ferrante, MD</investigator_full_name>
    <investigator_title>Female Pelvic Medicine and Reconstructive Surgery Attending</investigator_title>
  </responsible_party>
  <keyword>Recurrent Urinary Tract Infection</keyword>
  <keyword>Postmenopausal</keyword>
  <keyword>Vaginal Estrogen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Estrogens, Conjugated (USP)</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 21, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/73/NCT01958073/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>At the start of the study we began with the intent of 3 groups for analysis, separating the two forms of vaginal estrogen into separate groups and comparing them to a placebo group. Due to difficulties with recruitment, our protocol was amended so that the two vaginal estrogen groups were combined to one vaginal estrogen group compared to placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Conjugated Estrogen Vaginal Cream</title>
          <description>Conjugated estrogen vaginal cream 0.5g per vagina 2 times weekly&#xD;
Conjugated Estrogen Vaginal Cream</description>
        </group>
        <group group_id="P2">
          <title>Estradiol Ring</title>
          <description>Estradiol Ring per vagina every 3 months&#xD;
Estradiol Ring</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Per vagina 0.5g 2 times weekly&#xD;
Placebo</description>
        </group>
        <group group_id="P4">
          <title>Vaginal Cream Open Label</title>
          <description>Conjugated estrogen vaginal cream 0.5g per vagina 2 times weekly&#xD;
Conjugated Estrogen Vaginal Cream</description>
        </group>
        <group group_id="P5">
          <title>Estradiol Ring Open Label</title>
          <description>Estradiol Ring per vagina every 3 months&#xD;
Estradiol Ring</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Randomized Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Open Label Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>At the start of the study we began with the intent of 3 groups for analysis, separating the two forms of vaginal estrogen into separate groups and comparing them to a placebo group. Due to difficulties with recruitment, our protocol was amended so that the two vaginal estrogen groups were combined to one vaginal estrogen group compared to placebo.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Per vagina 0.5g 2 times weekly&#xD;
Placebo</description>
        </group>
        <group group_id="B2">
          <title>Vaginal Estrogen</title>
          <description>Conjugated estrogen vaginal cream 0.5g per vagina 2 times weekly&#xD;
OR&#xD;
Estradiol Ring per vagina every 3 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.5" spread="10.47"/>
                    <measurement group_id="B2" value="72.8" spread="8.4"/>
                    <measurement group_id="B3" value="70.15" spread="9.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.41" spread="7.09"/>
                    <measurement group_id="B2" value="30.33" spread="9.21"/>
                    <measurement group_id="B3" value="29.37" spread="8.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of UTIs in prior 12 months</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Current</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Former</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Never</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Marital Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Single</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Married</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Divorced/Separated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Widowed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Education</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Less than High School</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High School/GED</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Associates Degree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 year college</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Graduate School</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Caffeine use</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Pelvic Surgery</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Vaginal Estrogen</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hormone Replacement Therapy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Never</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Past</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Occurrence of UTI During Randomization</title>
        <description>The primary purpose of this study is to assess the efficacy of vaginal estrogen versus placebo at 6 months on the prevention of urinary tract infections (UTI) in postmenopausal women with history of recurrent UTI.</description>
        <time_frame>6 months of the randomized period</time_frame>
        <population>As treated. Vaginal estrogen groups were combined due to a protocol amendment.</population>
        <group_list>
          <group group_id="O1">
            <title>Vaginal Estrogen</title>
            <description>Conjugated Estrogen Vaginal Cream&#xD;
OR&#xD;
Estradiol Ring</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Per vagina&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of UTI During Randomization</title>
          <description>The primary purpose of this study is to assess the efficacy of vaginal estrogen versus placebo at 6 months on the prevention of urinary tract infections (UTI) in postmenopausal women with history of recurrent UTI.</description>
          <population>As treated. Vaginal estrogen groups were combined due to a protocol amendment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rates of UTI in Both Randomization Period and Within Placebo When Changed to Open Label Estrogen</title>
        <description>To assess overall rates of UTI over 6 months in postmenopausal women with history of recurrent UTI receiving vaginal estrogen (ring or cream).&#xD;
To compare rates of UTI between 6 and 12 months of those subjects initially randomized to placebo.</description>
        <time_frame>Assessed at 6 months for 'a'; assessed over 12 months for 'b'</time_frame>
        <population>As treated. Vaginal estrogen groups were combined due to a protocol amendment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo During Randomization</title>
            <description>Per vagina 0.5g 2 times weekly&#xD;
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Vaginal Estrogen</title>
            <description>Conjugated estrogen vaginal cream 0.5g per vagina 2 times weekly&#xD;
OR&#xD;
Estradiol Ring per vagina every 3 months</description>
          </group>
          <group group_id="O3">
            <title>Initial Placebo to Open Label Vaginal Estrogen</title>
            <description>Those participants initially randomized to placebo, during the period when they went on open label vaginal estrogen.</description>
          </group>
        </group_list>
        <measure>
          <title>Rates of UTI in Both Randomization Period and Within Placebo When Changed to Open Label Estrogen</title>
          <description>To assess overall rates of UTI over 6 months in postmenopausal women with history of recurrent UTI receiving vaginal estrogen (ring or cream).&#xD;
To compare rates of UTI between 6 and 12 months of those subjects initially randomized to placebo.</description>
          <population>As treated. Vaginal estrogen groups were combined due to a protocol amendment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No UTI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 UTI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 UTI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 UTI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Questionnaire: Female Sexual Function Index</title>
        <description>To assess the impact of treatment of recurrent UTI with vaginal estrogen on quality of life at 6 months in postmenopausal women with history of recurrent UTI. Female Sexual Function Index. Scale range 2-95. Lower score corresponds to worse functioning.</description>
        <time_frame>6 months of the randomized period</time_frame>
        <population>As treated. Vaginal estrogen groups were combined due to a protocol amendment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Per vagina 0.5g 2 times weekly&#xD;
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Vaginal Estrogen</title>
            <description>Conjugated estrogen vaginal cream 0.5g per vagina 2 times weekly&#xD;
OR&#xD;
Estradiol Ring per vagina every 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Questionnaire: Female Sexual Function Index</title>
          <description>To assess the impact of treatment of recurrent UTI with vaginal estrogen on quality of life at 6 months in postmenopausal women with history of recurrent UTI. Female Sexual Function Index. Scale range 2-95. Lower score corresponds to worse functioning.</description>
          <population>As treated. Vaginal estrogen groups were combined due to a protocol amendment.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.45" spread="27.83"/>
                    <measurement group_id="O2" value="30.64" spread="29.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Compliance During Randomization</title>
        <description>To assess compliance with vaginal estrogen (ring or cream) treatment at 6 months in postmenopausal women with history of recurrent UTI.</description>
        <time_frame>6 months of the randomized period</time_frame>
        <population>as treated, we did not collect data from the placebo group; although vaginal estrogen groups were combined in a protocol amendment for the primary outcome, they were not combined for this secondary outcome looking at compliance</population>
        <group_list>
          <group group_id="O1">
            <title>Conjugated Estrogen Vaginal Cream</title>
            <description>Conjugated estrogen vaginal cream 0.5g per vagina 2 times weekly&#xD;
Conjugated Estrogen Vaginal Cream</description>
          </group>
          <group group_id="O2">
            <title>Estradiol Ring</title>
            <description>Estradiol Ring per vagina every 3 months&#xD;
Estradiol Ring</description>
          </group>
        </group_list>
        <measure>
          <title>Compliance During Randomization</title>
          <description>To assess compliance with vaginal estrogen (ring or cream) treatment at 6 months in postmenopausal women with history of recurrent UTI.</description>
          <population>as treated, we did not collect data from the placebo group; although vaginal estrogen groups were combined in a protocol amendment for the primary outcome, they were not combined for this secondary outcome looking at compliance</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of UTI in Those Compliant With Treatment During Randomization</title>
        <description>To assess efficacy of vaginal estrogen at 6 months in those compliant with treatment.</description>
        <time_frame>6 months of the randomized period</time_frame>
        <population>as treated; although vaginal estrogen groups were combined in a protocol amendment for the primary outcome, they were not combined for this secondary outcome looking at compliance. Compliance was not assessed in placebo which was used as a comparator group for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Conjugated Estrogen Vaginal Cream</title>
            <description>Conjugated estrogen vaginal cream 0.5g per vagina 2 times weekly&#xD;
Conjugated Estrogen Vaginal Cream</description>
          </group>
          <group group_id="O2">
            <title>Estradiol Ring</title>
            <description>Estradiol Ring per vagina every 3 months&#xD;
Estradiol Ring</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Per vagina&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of UTI in Those Compliant With Treatment During Randomization</title>
          <description>To assess efficacy of vaginal estrogen at 6 months in those compliant with treatment.</description>
          <population>as treated; although vaginal estrogen groups were combined in a protocol amendment for the primary outcome, they were not combined for this secondary outcome looking at compliance. Compliance was not assessed in placebo which was used as a comparator group for this outcome.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Questionnaire: MESA I</title>
        <description>To assess the impact of treatment of recurrent UTI with vaginal estrogen on quality of life at 6 months in postmenopausal women with history of recurrent UTI. Medical, Epidemiologic, and Social Aspects of Aging Questionnaire (MESA) urinary incontinence questionnaire: stress urinary incontinence subscale. Subscale range 0-27. A higher score indicated more frequent symptoms.</description>
        <time_frame>6 months of the randomized period</time_frame>
        <population>As treated. Vaginal estrogen groups were combined due to a protocol amendment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Per vagina 0.5g 2 times weekly&#xD;
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Vaginal Estrogen</title>
            <description>Conjugated estrogen vaginal cream 0.5g per vagina 2 times weekly&#xD;
OR&#xD;
Estradiol Ring per vagina every 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Questionnaire: MESA I</title>
          <description>To assess the impact of treatment of recurrent UTI with vaginal estrogen on quality of life at 6 months in postmenopausal women with history of recurrent UTI. Medical, Epidemiologic, and Social Aspects of Aging Questionnaire (MESA) urinary incontinence questionnaire: stress urinary incontinence subscale. Subscale range 0-27. A higher score indicated more frequent symptoms.</description>
          <population>As treated. Vaginal estrogen groups were combined due to a protocol amendment.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.00" spread="7.27"/>
                    <measurement group_id="O2" value="9.86" spread="6.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Questionnaire: MESA II</title>
        <description>To assess the impact of treatment of recurrent UTI with vaginal estrogen on quality of life at 6 months in postmenopausal women with history of recurrent UTI. Medical, Epidemiologic, and Social Aspects of Aging Questionnaire (MESA) urinary incontinence questionnaire: urgency urinary incontinence subscale. Subscale range 0-18. High score indicates more frequent symptoms.</description>
        <time_frame>6 months of the randomized period</time_frame>
        <population>As treated. Vaginal estrogen groups were combined due to a protocol amendment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Per vagina 0.5g 2 times weekly&#xD;
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Vaginal Estrogen</title>
            <description>Conjugated estrogen vaginal cream 0.5g per vagina 2 times weekly&#xD;
OR&#xD;
Estradiol Ring per vagina every 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Questionnaire: MESA II</title>
          <description>To assess the impact of treatment of recurrent UTI with vaginal estrogen on quality of life at 6 months in postmenopausal women with history of recurrent UTI. Medical, Epidemiologic, and Social Aspects of Aging Questionnaire (MESA) urinary incontinence questionnaire: urgency urinary incontinence subscale. Subscale range 0-18. High score indicates more frequent symptoms.</description>
          <population>As treated. Vaginal estrogen groups were combined due to a protocol amendment.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.82" spread="5.76"/>
                    <measurement group_id="O2" value="4.79" spread="3.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Questionnaire: Pelvic Floor Disability Index</title>
        <description>To assess the impact of treatment of recurrent UTI with vaginal estrogen on quality of life at 6 months in postmenopausal women with history of recurrent UTI. Pelvic Floor Disability Index. Scale range 0-100. Higher score corresponds to increased bother.</description>
        <time_frame>6 months of the randomized period</time_frame>
        <population>As treated. Vaginal estrogen groups were combined due to a protocol amendment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Per vagina 0.5g 2 times weekly&#xD;
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Vaginal Estrogen</title>
            <description>Conjugated estrogen vaginal cream 0.5g per vagina 2 times weekly&#xD;
OR&#xD;
Estradiol Ring per vagina every 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Questionnaire: Pelvic Floor Disability Index</title>
          <description>To assess the impact of treatment of recurrent UTI with vaginal estrogen on quality of life at 6 months in postmenopausal women with history of recurrent UTI. Pelvic Floor Disability Index. Scale range 0-100. Higher score corresponds to increased bother.</description>
          <population>As treated. Vaginal estrogen groups were combined due to a protocol amendment.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.88" spread="56.29"/>
                    <measurement group_id="O2" value="55.53" spread="31.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Questionnaire: Pelvic Floor Impact Questionnaire</title>
        <description>To assess the impact of treatment of recurrent UTI with vaginal estrogen on quality of life at 6 months in postmenopausal women with history of recurrent UTI. Pelvic Floor Impact Questionnaire. Scale range 0-300. Higher score corresponds to increasing bother.</description>
        <time_frame>6 months of the randomized period</time_frame>
        <population>As treated. Vaginal estrogen groups were combined due to a protocol amendment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Per vagina 0.5g 2 times weekly&#xD;
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Vaginal Estrogen</title>
            <description>Conjugated estrogen vaginal cream 0.5g per vagina 2 times weekly&#xD;
OR&#xD;
Estradiol Ring per vagina every 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Questionnaire: Pelvic Floor Impact Questionnaire</title>
          <description>To assess the impact of treatment of recurrent UTI with vaginal estrogen on quality of life at 6 months in postmenopausal women with history of recurrent UTI. Pelvic Floor Impact Questionnaire. Scale range 0-300. Higher score corresponds to increasing bother.</description>
          <population>As treated. Vaginal estrogen groups were combined due to a protocol amendment.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.08" spread="44.01"/>
                    <measurement group_id="O2" value="9.86" spread="14.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Questionnaire: Estimated Percentage of Improvement</title>
        <description>To assess the impact of treatment of recurrent UTI with vaginal estrogen on quality of life at 6 months in postmenopausal women with history of recurrent UTI. Estimated Percentage of Improvement. Scale range 0-100. Higher score corresponds to more improvement.</description>
        <time_frame>6 months of the randomized period</time_frame>
        <population>As treated. Vaginal estrogen groups were combined due to a protocol amendment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Per vagina 0.5g 2 times weekly&#xD;
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Vaginal Estrogen</title>
            <description>Conjugated estrogen vaginal cream 0.5g per vagina 2 times weekly&#xD;
OR&#xD;
Estradiol Ring per vagina every 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Questionnaire: Estimated Percentage of Improvement</title>
          <description>To assess the impact of treatment of recurrent UTI with vaginal estrogen on quality of life at 6 months in postmenopausal women with history of recurrent UTI. Estimated Percentage of Improvement. Scale range 0-100. Higher score corresponds to more improvement.</description>
          <population>As treated. Vaginal estrogen groups were combined due to a protocol amendment.</population>
          <units>percentage of improvement</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.00" spread="35.48"/>
                    <measurement group_id="O2" value="74.64" spread="25.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected up to 1 year after start of study participation</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Per vagina 0.5g 2 times weekly&#xD;
Placebo</description>
        </group>
        <group group_id="E2">
          <title>Vaginal Estrogen Cream Randomization</title>
          <description>Conjugated estrogen vaginal cream 0.5g per vagina 2 times weekly</description>
        </group>
        <group group_id="E3">
          <title>Vaginal Estrogen Ring Randomization</title>
          <description>Estradiol Ring per vagina every 3 months</description>
        </group>
        <group group_id="E4">
          <title>Vaginal Estrogen Cream Open Label</title>
          <description>Conjugated estrogen vaginal cream 0.5g per vagina 2 times weekly</description>
        </group>
        <group group_id="E5">
          <title>Vaginal Estrogen Ring Open Label</title>
          <description>Estradiol Ring per vagina every 3 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Difficult recruitment requiring several modifications to the study design, single-blind nature of the trial, underpowered for secondary outcomes.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Kimberly Ferrante</name_or_title>
      <organization>Kaiser Permanente San Diego</organization>
      <phone>6199801439</phone>
      <email>klf0409@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

